OBJECTIVE：To provide theoretical support for the scientific and reasonable policy-making of 23-valent pneumococcal polysaccharide vaccine （PPV-23） in elderly. METHODS： Retrieved from CJFD， Wanfang Database， Elsevier and PubMed， literature about the pharmacoeconomics evaluation of PPV-23 in elder were selected and statistically analyzed in respects of cost studies， effect indexes and research perspectives. RESULTS： Totally 13 literatures were included， involving 900 472 patients， who were older than 60 years old. Study locations were mainly Colombia， the United States， Italy， Belgium and China. Study results showed， each additional quality-adjusted life-year（QALY） cost was between $ 9 239-$ 33 000 in respect of cost； cost-effectiveness ratio was between $ 9 239-$ 45 161/QALY in respect of effect indexes. Most researches showed PPV-23 in elderly older than 65 years old had certain cast-effectiveness. Only a research in Netherlands held the idea that PPV-23 in elderly was not considered cost-effectiveness.CONCLUSIONS：Putting PPV-23 inelderly has certain cost-effecctiveness and most countries has put it into national immunization program. The present researches can’t ensure the economy of putting ppv-23 in elderly in china，so it needs more researches with high quality to ensure it.